Norman E. “Ned” Sharpless, M.D., becomes the 15th director of the National Cancer Institute (NCI). He comes to NCI from the University of North Carolina School of Medicine, where he was director of the Lineberger Comprehensive Cancer Center.

TMIST, the first randomized trial comparing two types of digital mammography for breast cancer screening, is enrolling participants. Developed by ECOG-ACRIN and NCI, the trial is comparing 2-D and 3-D mammography for finding breast cancers.

Dr. Douglas R. Lowy and Dr. John T. Schiller of the National Cancer Institute receive the 2017 Lasker-DeBakey Clinical Medical Research Award for their significant research leading to the development of HPV vaccines.

A new NCI study demonstrates the feasibility of a comprehensive screening protocol for patients with Li-Fraumeni syndrome, a rare inherited disorder that leads to a higher risk of developing certain cancers.

The nationwide precision medicine trial will enroll children and adolescents with advanced cancers that haven’t responded to standard therapy to explore treatments targeted at specific genetic mutations.

Only two drugs are FDA-approved for liver cancer. This study of hepatocellular carcinoma found genetic alterations in tumors—including mutations in tumor-suppressing genes and high expression of immune checkpoint genes—that could be targets for drugs that already exist.

A new study shows that the number of women in the United States living with distant metastatic breast cancer (MBC), the most severe form of the disease, is growing. This is likely due to the aging of the U.S. population and improvements in treatment.

According to the latest Annual Report to the Nation on the Status of Cancer, 1975-2014, overall cancer death rates continue to decrease in men, women, and children for all major racial and ethnic groups. But more work remains for some cancers.